Tinea pedis (Athlete Foot) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Tinea pedis (Athlete Foot) – Pipeline Review, H2 2016’, provides an overview of the Tinea pedis (Athlete Foot) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tinea pedis (Athlete Foot), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tinea pedis (Athlete Foot) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Tinea pedis (Athlete Foot)

The report reviews pipeline therapeutics for Tinea pedis (Athlete Foot) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Tinea pedis (Athlete Foot) therapeutics and enlists all their major and minor projects

The report assesses Tinea pedis (Athlete Foot) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Tinea pedis (Athlete Foot)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Tinea pedis (Athlete Foot)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tinea pedis (Athlete Foot) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Anacor Pharmaceuticals Inc

Astellas Pharma Inc

Biolab Farmaceutica Ltda

Blueberry Therapeutics Ltd

Dermala Inc

Helix BioMedix Inc

Novan Inc

Novoteris LLC

Sol-Gel Technologies Ltd

Viamet Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Tinea pedis (Athlete Foot) Overview 6

Therapeutics Development 7

Pipeline Products for Tinea pedis (Athlete Foot) - Overview 7

Tinea pedis (Athlete Foot) - Therapeutics under Development by Companies 8

Tinea pedis (Athlete Foot) - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Tinea pedis (Athlete Foot) - Products under Development by Companies 12

Tinea pedis (Athlete Foot) - Companies Involved in Therapeutics Development 13

Anacor Pharmaceuticals Inc 13

Astellas Pharma Inc 14

Biolab Farmaceutica Ltda 15

Blueberry Therapeutics Ltd 16

Dermala Inc 17

Helix BioMedix Inc 18

Novan Inc 19

Novoteris LLC 20

Sol-Gel Technologies Ltd 21

Viamet Pharmaceuticals Inc 22

Tinea pedis (Athlete Foot) - Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

AN-2718 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

AS-2077715 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

BB-2603 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

dapaconazole - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Drug for Athlete's Foot - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

E-06 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

HB-1275 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

nitric oxide - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SB-208 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

VT-1161 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Tinea pedis (Athlete Foot) - Dormant Projects 45

Tinea pedis (Athlete Foot) - Product Development Milestones 46

Featured News & Press Releases 46

Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program 46

Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting 46

Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis 47

Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161 47

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

List of Tables

Number of Products under Development for Tinea pedis (Athlete Foot), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Tinea pedis (Athlete Foot) – Pipeline by Anacor Pharmaceuticals Inc, H2 2016 13

Tinea pedis (Athlete Foot) – Pipeline by Astellas Pharma Inc, H2 2016 14

Tinea pedis (Athlete Foot) – Pipeline by Biolab Farmaceutica Ltda, H2 2016 15

Tinea pedis (Athlete Foot) – Pipeline by Blueberry Therapeutics Ltd, H2 2016 16

Tinea pedis (Athlete Foot) – Pipeline by Dermala Inc, H2 2016 17

Tinea pedis (Athlete Foot) – Pipeline by Helix BioMedix Inc, H2 2016 18

Tinea pedis (Athlete Foot) – Pipeline by Novan Inc, H2 2016 19

Tinea pedis (Athlete Foot) – Pipeline by Novoteris LLC, H2 2016 20

Tinea pedis (Athlete Foot) – Pipeline by Sol-Gel Technologies Ltd, H2 2016 21

Tinea pedis (Athlete Foot) – Pipeline by Viamet Pharmaceuticals Inc, H2 2016 22

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Stage and Target, H2 2016 25

Number of Products by Stage and Mechanism of Action, H2 2016 27

Number of Products by Stage and Route of Administration, H2 2016 29

Number of Products by Stage and Molecule Type, H2 2016 31

Tinea pedis (Athlete Foot) – Dormant Projects, H2 2016 45

List of Figures

List of Figures

Number of Products under Development for Tinea pedis (Athlete Foot), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Targets, H2 2016 24

Number of Products by Stage and Targets, H2 2016 24

Number of Products by Mechanism of Actions, H2 2016 26

Number of Products by Stage and Mechanism of Actions, H2 2016 26

Number of Products by Routes of Administration, H2 2016 28

Number of Products by Stage and Routes of Administration, H2 2016 28

Number of Products by Molecule Types, H2 2016 30

Number of Products by Stage and Molecule Types, H2 2016 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports